Patients usually have serious complications of thrombosis and bleeding by eating anticoagulation medicine for their residual lives after mechanical valve replacement operation. Tissue-type plasminogen activator (tPA) could target thrombolysis by activating plasminogen to fibrinolysin. In this study, we recombined a retroviral vector pLEGFP-N1-tPA and cultured purified packaging cells PT67/pLEGFP-N1-tPA to produce high-titer retrovirus. In vitro, two target cells, endothelial cell of umbilical vein (ECUV) 304 and heart muscle cell (HMC) that consist of endocardium and heart muscle, were infected by pLEGFP-N1-tPA. The results demonstrated that exogenous tPA was successfully transferred into ECUV304 and HMC. tPA in the two cells shows significant thrombolysis in plasma plate and the activity and content of tPA were high. Furthermore, in vivo, no thrombus was seen on the surface of Dacron patches (the same material making up a ring of mechanical valve) by tPA locally transferring around Dacron patches that were transplanted in the inferior caval veins of rabbits. tPA was successfully transferred into the local inferior caval vein. Activity and content of tPA were high in local tissue and blood and thrombolysis was effectively demonstrated by tPA rapidly, efficiently and long expressing. This laid the foundation for study and appliance of the tPA gene valve.
Patients usually have serious complications of thrombosis and bleeding by eating anticoagulation medicine for their residual lives after mechanical valve replacement operation. Tissue-type plasminogen activator (tPA) could target thrombolysis by activating plasminogen to fibrinolysin. In this study, we recombined a retroviral vector pLEGFP-N1-tPA and cultured purified packaging cells PT67/pLEGFP-N1-tPA to produce high-titer retrovirus. In vitro, two target cells, endothelial cell of umbilical vein (ECUV) 304 and heart muscle cell (HMC) that consist of endocardium and heart muscle, were infected by pLEGFP-N1-tPA. The results demonstrated that exogenous tPA was successfully transferred into ECUV304 and HMC. tPA in the two cells shows significant thrombolysis in plasma plate and the activity and content of tPA were high. Furthermore, in vivo, no thrombus was seen on the surface of Dacron patches (the same material making up a ring of mechanical valve) by tPA locally transferring around Dacron patches that were transplanted in the inferior caval veins of rabbits. tPA was successfully transferred into the local inferior caval vein. Activity and content of tPA were high in local tissue and blood and thrombolysis was effectively demonstrated by tPA rapidly, efficiently and long expressing. This laid the foundation for study and appliance of the tPA gene valve. Valve replacement is an efficient method of treating valve dysfunction of heart valve diseases. [1] [2] [3] However, those patients who have had valve replacement operations with mechanical valves should take anticoagulation medicine for the rest of their lives where serious complications of thrombosis and over anticoagulation bleeding have been observed. [4] [5] [6] Tissue-type plasminogen activator (tPA) has a special and thorough thrombolysis on the thrombus in dynamic blood circulation. [7] [8] [9] [10] [11] The effect of tPA is very soon inhibited by plasminogen activator inhibitor-1 cooperating with it. [12] [13] [14] So target therapy of tPA demonstrates its highlight value. 15, 16 pLEGFP-N1 is a retroviral vector containing enhanced green fluorescent protein (EGFP) that could easily be observed with 35-fold amplification than green fluorescent protein. [17] [18] [19] Important exogenous genes inserted into the multiple cloning site of pLEGFP-N1 could be integrated into the genome of host cells by retroviral vector and expressed rapidly, efficiently and in the long term. [20] [21] [22] [23] [24] EGFP gene merged with the inserted gene in the retroviral vector. In this trial, we constructed the recombinant retroviral vector pLEGFP-N1-tPA, transferring it into the endothelial cell of umbilical vein (ECUV) 304 cells and cardiac myocytes in vitro to check the thrombolysis of exogenous tPA. In experiment animals, pLEGFP-N1-tPA was targeted around the Dacron patches that were sewed into the cavea of inferior caval veins of rabbits. We saw the target thrombolysis of tPA on the thrombi on the surface of Dacron patches. This put the base for the tPA gene valve.
We successfully constructed a pLEGFP-N1-tPA nonreplicative retroviral vector by inserting a tPA gene containing a kozak sequence into a multiple cloning site of pLEGFP-N1 (Clontech, a Takara Bio Company) with restriction enzyme cutting. We also cultured a purified packaging PT67 (Clontech)/pLEGFP-N1-tPA cells line all containing EGFP that could produce high retrovirus titer, 1 Â 10 7 colony forming units (CFU)/ml, by transfecting NIH 3T3 cells (detailed information in Supplementary  Figure) . 25, 26 An endothelial cell is the main cell making up the endocardium. So we chose ECUV304 cell (donated by Dr MF Wu) as one target cell in vitro. We infected ECUV304 cells with a supernatant of purified PT67/pLEGFP-N1-tPA or PT67/pLEGFP-N1 and constructed a purified ECUV304/pLEGFP-N1-tPA cells line (Figure 1a ). In the plasma plate thrombus model, 27 ,28 the supernatant of purified ECUV304/pLEGFP-N1-tPA cells had significant thrombolysis area, whereas none of the ECUV304/pLEGFP-N1 cells and Dulbecco's modified Eagle's medium (DMEM)+10% neonate calf serum (NCS) did (Figure 1b) ).
Using enzyme linked immunosorbent assay doubleantibodies sandwich method (following the instruction provided by the manufacturer), the content of tPA in purified ECUV304/pLEGFP-N1-tPA cells was 716.27 ng/ 10 6 cells/24 h compared to 50.15 ng/10 6 cells/24 h in ECUV304/pLEGFP-N1 cells. EGFP-merged tPA could be observed on the cell surface and in medium by confocal microscopy. tPA-antibody (tPA-Ab) diluted up to 1:5000 was used as first antibody. Second antibody was peroxidase-conjugated immunopure goat anti-rabbit IgG (H+L) diluted 1:20 000. Western blot checked out exogenous 95 kDa tPA-merged protein (tPA 68 KD+ EGFP 27 KD) in supernatant of purified ECUV304/ pLEGFP-N1-tPA cells and none in supernatant of ECUV304/pLEGFP-N1 cells and DMEM+10% NCS (Figure 1c) . Heart muscle cells (HMC) consists mostly of cardiac cells, and therefore we chose HMC from 1-4 days neonate mice as another target cell in vitro. HMC were taken from 1-4 days heart of neonate mice from Tongji Medical College Animal Centre of Huazhong University of Science and Technology (License SYXK Hubei). HMC were successfully infected with supernatant of purified PT67/pLEGFP-N1-tPA or PT67/ pLEGFP-N1 (Figure 1d) . We also observed a drop in the lysis zone of thrombi in plasma plate by supernatant of HMC/pLEGFP-N1-tPA but no thrombolysis area drop by supernatant of HMC/pLEGFP-N1 and DMEM+10% NCS (Figure 1e ). Activity of tPA in HMC/pLEGFP-N1-tPA was 464.27 U/10 6 cells/24 h. The content of tPA in HMC/pLEGFP-N1-tPA was 607.34 ng/10 6 cells/24 h and simultaneously 48.19 ng/10 6 cells/24 h in HMC/ pLEGFP-N1. Western blot showed that there was an exogenous 95 kDa tPA-merged protein (tPA 68 kDa+ EGFP 27 kDa) band in the supernatant of HMC/ pLEGFP-N1-tPA and no band in supernatant of HMC/ pLEGFP-N1 and DMEM+10% NCS (Figure 1f) .
To test the target therapeutic efficacy of pLEGFP-N1-tPA on thrombi in vivo, we designed an animal model. All animal experiments were performed in compliance with the animal protection policy of the Chinese government (license SYXK Hubei) and we have adhered to the standards of our institution's bioethics and bio-security committees. Seventy New Zealand rabbits came from Tongji Medical College animal centre of Huazhong University of Science and Technology and were randomly divided into three groups according to the different handling methods, including local pLEGFP-N1-tPA-transferred group (A: gene therapy group, 30 animals), pLEGFP-N1-transferred group (B: control group, 20 animals), DMEM+10% NCS-injected group (C: blank control group, 20 animals). We sewed a 2 Â 3 mm Dacron patch with 9-0 non-trauma line in the cavea of the middle of a 2 cm dissected inferior caval vein under the renal vein of rabbit. One short edge touched the wall of veins. The surface of Dacron patch was vertical with the axle of the inferior caval vein. We injected 400 ml of supernatant of PT67/pLEGFP-N1-tPA or PT67/pLEGFP-N1 or DMEM+ 10% NCS in addition to 10 mg/ml polybrene under the endomembrane of a 2 cm inferior caval vein without penetrating the endomembrane by micro-operation. After No thrombus was observed on the surface of Dacron patches in local pLEGFP-N1-tPA-transferred and untransplanted groups under stereoscopy ( Â 160 fold) and electronic microscopy ( Â 500 fold). On the other hand, we could see thrombi on the surface of Dacron pieces in the pLEGFP-N1 transferred group and the blank control group (Figures 2a and b) . One centimeter of harvested inferior caval vein was rapidly frozen-cut with 5 mm section for confocal to observe EGFP expressing. In the gene therapy group, all sections had much EGFP. The pLEGFP-N1-transferred group also had much EGFP, but in the blank control group, no EGFP was seen (Figure 2c ). Another 1 cm of harvested inferior caval vein was smashed and the supernatant of homogenate for thrombolysis observation was collected in plasma plate, activity and content of tPA. All supernatant from the gene therapy group veins apparently had a thrombolysis zone in plasma plate and none had that appearance from another two control groups (Figure 2d) 2 , respectively. The contents of tPA in the gene therapy group were higher than those in the control group and the blank control group (Po0.01; Table 2 ). No significant differences in tPA contents and activities were found in the gene therapy group between days 2and 75 (P40.05; Tables 1 and 2 ). Exogenous tPA bands were found in the inferior caval veins of the gene therapy group through western blot and no exogenous tPA bands were found in the veins of the control group and the blank control group (Figure 2e ).
In the gene therapy group, blood from the inferior caval vein around Dacron patches after treatment had a significant thrombolysis zone in plasma plate and blood from the left external jugular vein after treatment did not have thrombolysis area in plasma plate and no significant tPA activity. In the gene therapy group, tPA content in blood from inferior caval vein around Dacron Table 3) .
tPA belongs to a serine protein hydrolase and is a secreted single-chain protein with 527 amino acids. It is the natural activator of the thrombolytic system in the blood. tPA could activate fibrinogen to become fibrinolysin, and the fibrin within the thrombus was lysed by fibrinolysin. So the thrombus was cleaved. Etong et al. 30 seed the vascular smooth muscle cells transferred tPA on the endomembrane of the artificial stent and transplanted the stent into the animals. The stent had a lift anti-thrombus. Jiang et al. 31 locally used tPA to prevent restenosis of the veins transplant bridge. Seltzer et al.
32
injected tPA into the left atrial to treat one child with thrombus after mitral valve replacement. tPA has excellent characteristics to target lysing thrombus. pLEGFP-N1 is an amphotropic retroviral system with cytomegalovirus immediate early promoter and kozak sequence at the start of EGFP to further increase the translation efficiency in eukaryotic cells. If EGFP was expressed, the exogenous inserted gene must be expressed with accompany. In this study, the kozak sequence designed in the upstream primer could secondly enhance the expression of exogenous tPA within the host cells. The retroviral elements in pLEGFP-N1 are derived from a Moloney murine leukemia virus (MoMuLV). 33 pLEGFP-N1 does not contain the structural gag, pol and env genes necessary for retroviral particle formation and replication; however, these genes are stably integrated in the packaging cell genome. 34 A retroviral vector was used for clinical therapy. Nishino T et al. 35 used the g-retrovirus as a vector to treat the human gamma-globin disease and got better results.
In an in vitro study, we successfully infected pLEGFP-N1-tPA into ECUV304 cells and constructed a purified ECUV304/pLEGFP-N1-tPA cells line. The EGFP-merged tPA was expressed fast in ECUV304 cells (about 20 h post-infection). Approximately 60 days consumed on the construction of purified ECUV304/pLEGFP-N1-tPA identified that tPA could long express by retroviral vector delivery. The supernatant of purified ECUV304/ pLEGFP-N1-tPA cells apparently had a lysis zone on thrombi in vitro. tPA was high in purified ECUV304/ pLEGFP-N1-tPA cells. 36 Furthermore, western blot checked out tPA in the supernatant of purified ECUV304/pLEGFP-N1-tPA cells. Because tPA was secreted protein, we saw the EGFP-merged tPA on the cell surface and in medium. Until now, no cardiac myocyte line was constructed for use because that they could be passaged to a limited extent. We successfully infected HMC with pLEGFP-N1-tPA and the infected proportion was high. The supernatant of HMC/pLEGFP-N1-tPA had shown significant thrombolysis in vitro. Also, the activity and content of tPA in HMC/pLEGFP-N1-tPA were at high levels. Meanwhile, western blot confirmed the existing of exogenous tPA. There was a phenomenon that fluorescence of EGFP-merged tPA was weaker than that of simple EGFP under a fluorescent microscope or a confocal microscope, which would be because of light reflection on the folded protein of EGFP and tPA. All of the above validated the effectiveness of the recombinant retrovirus pLEGFP-N1-tPA in vitro. pLEGFP-N1-tPA could efficiently infect ECUV304 and HMC, and the delivered tPA had an apparent long effect on thrombi.
In an in vivo study, we did not observe a thrombus on the surface of the untransplanted and pLEGFP-N1-tPAtransferred Dacron patches. The control group and blank control group Dacron patches had thrombi on the surface. In the gene therapy group, many strong EGFP were seen in the 5-mm section of harvested inferior caval veins under the confocal microscope. The EGFP level did not differ significantly in harvested inferior caval veins between days 2 and 75. The EGFP expression identified tPA expression that was early, efficient and long. EGFP could be seen in the harvested veins of the pLEGFP-N1-transferred group (control group). The absence of EGFP There was no variance of tPA activity in the gene therapy group veins between the two time points. This suggested that we successfully transferred pLEGFP-N1-tPA into the genome of rabbit inferior caval vein cells and that the stable heredity of tPA was passaged down. The content of tPA in the gene therapy group was significantly higher than those in the control group and the blank control group. No difference of tPA contents was found at the two time points in the gene therapy group. This told us that tPA expression in the gene therapy group at the two time points was early, rapid and stable. Why was no thrombus seen on the surface of Dacron patches transplanted in the gene therapy group? In the gene therapy group, except for high tPA in intrinsic to the treated tissue that could be highly secreted into the blood, blood in the inferior caval vein around Dacron patches after treatment had significant tPA activity and high-level tPA contents at two time points after operation. On the other hand, blood from peripheral in the gene therapy group after treatment had no tPA activity in plasma plate and tPA contents were very low. Meanwhile, tPA contents in blood from the anatomied inferior caval vein before treatment were also very low. All the above told us that the delivered tPA effect was locally not in remote or systematically that the tPA effect was in for a relatively long time. In the control group and the blank control group, tPA contents in blood from the inferior caval vein around Dacron patches after treatment were very low. So, thrombi were seen on the surface of Dacron patches transplanted in control group and blank control group. Why was in gene therapy group tPA high in blood from inferior caval vein around Dacron patches, but low in blood from peripheral circulation after treatment? Because plasminogen activator inhibitor-1 rapidly cooperated with tPA when tPA circulated in blood from its resource. Early, rapid and relatively long expression of tPA in locally pLEGFP-N1-tPA-transferred animals caters to the demand that patients need early and residual life anticoagulation after mechanical valve replacement. This laid the foundation for study and appliance of the tPA gene valve. Table 3 In gene therapy group, tPA contents (ng/ml) in blood were compared each other. Meanwhile, tPA contents (ng/ml) in blood from local were compared among gene therapy group, control group (empty vector injected group) and blank control group (DMEM+10% neonate calf serum injected group) ( x7s) 
